Title: Assessment of the Role of Autologous Platelet-Rich Plasma (PRP) Injection in the

Treatment of Chronic Discogenic Low Back Pain (CDLBP).

Background: Millions of people worldwide suffer from chronic low back pain (CLBP), which
has significant negative effects on their physical, psychological, and financial well-being.
Chronic discogenic low back pain (CDLBP) is a common illness affecting a large section of the
population. Traditional therapeutic procedures frequently produce limited results, prompting the
investigation of alternative remedies. This includes a regimen of exercises tailored to strengthen
back muscles, improve posture, and increase spinal flexibility. Therapists may also employ
techniques such as manual therapy, heat therapy, and ultrasound to enhance mobility and relieve
pain. Prescriptions like nonsteroidal anti-inflammatory drugs (NSAIDs) or muscle relaxants or
steroids are commonly used to reduce inflammation and pain. Key lifestyle changes include
weight management to reduce the load on the spine and ergonomic adjustments to improve
posture during daily activities and work. In recent years, intradiscal autologous platelet-rich
plasma (PRP) injections have emerged as a promising treatment for chronic back pain due to
their regenerative properties. This study sought to evaluate the procedure's effectiveness and
provide judgments on its applicability

AIM: The primary aim of this study is to evaluate the efficacy of autologous platelet-rich plasma
(PRP) in reducing pain and enhancing physical function in patients suffering from chronic
discogenic back pain.

Methods: A total of 37 patients diagnosed with CDLBP were enrolled in this prospective
study. Each patient received an autologous PRP injection administered under fluoroscopic
guidance into the affected intervertebral disc. Pain and functional outcomes were assessed using
the Visual Analog Scale (VAS) for pain and the Oswestry Disability Index (ODI) at baseline, 1
month, 3 months, and 6 months post-injection.

Results: Significant reductions in VAS scores were observed at all follow-up points compared
to baseline (p < 0.05). The mean VAS score decreased from 6.2 (1.33) at baseline to 1.7 (1.73) at
6 months. The mean ODI score significantly decreased from 24.7 (SD = 5.53) at baseline to 7.2
(SD = 5.72) at the end line (p-value < 0.0001), indicating a substantial improvement in
functional disability levels following intradiscal PRP injection.

Conclusion: Autologous PRP injection appears to be a safe and effective treatment for
reducing pain and improving function in patients with chronic discogenic low back pain. Further
randomized controlled trials are warranted to confirm these findings and establish standardized
treatment protocols.